Cancer-on-Chip: Modeling the Tumor Microenvironment with Microfluidics
Cancer-on-chip technologies are transforming oncology research by enabling the precise replication of the tumor microenvironment (TME) using advanced microfluidic systems. Unlike traditional in vitro models, these platforms recreate the complex interactions between tumor cells, extracellular matrix, biochemical signals, and mechanical forces. This page explores how microfluidic cancer models capture key processes such as metastasis, organ-specific colonization, and drug response, while supporting the development of more predictive and personalized therapies.
Role of Tumor Microenvironment in Cancer-on-a-Chip Models
The tumor microenvironment (TME) refers to the full range of cellular and non-cellular components that surround and interact with tumor cells. Rather than serving as a passive backdrop, it is a dynamic, complex, and highly heterogeneous environment that plays an active and critical role in cancer initiation, progression, treatment resistance, and metastasis (1)(2).
Metastasis and Extravasation
During metastasis, tumor cells detach from the primary tumor, invade the extracellular matrix (ECM). Subsequently, they intravasate blood or lymphatic vessels, survive in circulation and subsequently extravasate to colonize specific metastatic niches in distant organs such as the bone, brain, or liver. These niches are shaped by both biochemical signals and biophysical constraints. (2)
Extravasation process is known to be driven not only by the tumour cellular composition but also by the microenvironment of the tissue. Tumor cells first adhere to the vascular endothelium through interactions involving selectins and integrins, followed by endothelial barrier disruption and transendothelial migration. These processes are strongly influenced by TME-derived signals, including chemokine gradients (e.g., CXCR4–CXCL12), inflammatory cytokines, and factors secreted by stromal and immune cells such as macrophages and fibroblasts. In addition, biophysical features of the TME, such as vascular permeability, shear stress, and ECM stiffness, is a critical parameter in facilitating or restricting tumor cell extravasation. Furthermore, the epithelial–mesenchymal transition (EMT) plays a pivotal role in this cascade by enabling tumor cells to acquire enhanced migratory and invasive capabilities, loss of cell–cell adhesion, and increased resistance to apoptosis. The epithelial–mesenchymal transition is tightly regulated by TME-derived cues, including cytokines and interactions with stromal components, thereby promoting intravasation, survival in circulation, and ultimately extravasation at distant sites.
Microfluidic technologies, such as cancer-on-a-chip platforms, have made it possible to faithfully recapitulate this complexity in vitro, leading to major insights. These include the role of interstitial flow in autologous chemotaxis and the impact of ECM stiffness on tumor invasion (2). Such advances are paving the way for therapies that target not only tumor cells themselves, but the entire ecosystem in which they evolve.
Organ-Specificity in Cancer-on-chip
The “seed and soil” hypothesis, first proposed by Stephen Paget, states that metastasis depends on the interaction between cancer cells (the “seeds”) and the specific microenvironment of target organs (the “soil”), meaning that tumor cells preferentially colonize organs whose biochemical and physical conditions are favorable to their growth. This organ-specific behavior cannot be properly captured by generic in vitro models, since each tissue provides a unique combination of cellular composition, vascularization, and mechanical cues. Consequently, it justifies the development of microfluidic organ-on-chip systems that faithfully reproduce specific target organ microenvironments, allowing precise control of cell–cell interactions and physiological conditions. Such platforms enable more accurate modeling of metastatic processes and drug responses by mimicking the “soil” that governs cancer cell colonization. (3)
- Ovarian cancer:
The complex interactions between ovarian tumors and the vascular system are modelled on the OvCa-Chip that recreates a three-dimensional interface between human ovarian cancer cells and a perfused endothelial lumen separated by a porous membrane. This platform enables the study of platelet extravasation under physiological shear stress and highlights the dynamic role of the endothelium in vascular disruption, cytokine signaling, and barrier dysfunction induced by tumor cells. It further provides a powerful alternative to murine models by allowing fine mechanistic dissection and therapeutic testing, as illustrated by the restoration of endothelial integrity and inhibition of platelet infiltration following atorvastatin treatment. (4)
- Intestinal cancer
To model intestinal cancer in a physiologically relevant manner, a gut-on-a-chip platform has been design. This chip enables reproducible 3D epithelial morphogenesis by controlling basolateral signaling, particularly through the removal of morphogen antagonists, without requiring complex genetic engineering. By integrating microfluidic flow, shear stress, and peristalsis-like mechanical stimulation, this system recreates key aspects of the crypt–villus architecture absent in conventional static cultures. As a result, it provides a powerful tool to investigate colorectal tumor development by capturing both spatial epithelial organization and dynamic microenvironmental cues. (5)
- Brest cancer-bone interface :
To model the complex processes underlying breast cancer bone metastasis, a breast cancer-bone interface has been designed as a fully humanized, multi-compartment microfluidic platform integrating osteotropic breast cancer spheroids, sympathetic neurons, and primary human osteoclasts cultured on native mineralized bone slices. The incorporation of Quake valves enables precise and reversible control of inter-compartmental paracrine signaling, allowing fine dissection of directional cell-cell communication. This system reveals that indirect synergistic interactions between neurons and osteoclasts enhance tumor aggressiveness, underscoring the key role of neuro-bone crosstalk in metastatic progression. (6)
Cancer-on-a-chip for Personalized Medicine
Cancer-on-a-chip platforms enable personalized therapy testing by integrating patient-derived tumor biopsies with autologous immune cells, allowing real-time evaluation of treatments within a faithfully reconstructed tumor microenvironment. Moreover, multi-organ chip systems combining tissues like liver, intestine, bone marrow, and tumor have demonstrated the ability to quantitatively predict human pharmacokinetic parameters, consistent with clinical data, paving the way for individualized dosing strategies prior to clinical trials. In the long term, these technologies could evolve into fully personalized “living avatars” built from a patient’s own induced pluripotent stem cells, enabling optimized treatment selection and the design of targeted early-phase trials.
Additionally, cancer-on-a-chip models offer the potential to study drug responses across diverse patient subpopulations and comorbidities, overcoming many ethical and logistical limitations of traditional clinical studies.(7)
Microfluidic Technologies in Cancer-on-a-Chip Systems
There are many different types of organ-on-chip cancer models, which vary both in their architecture and in the diversity of cellular components they incorporate to better reproduce the tumor microenvironment.
For instance, epithelium-based lung cancer chips, as developed by Hassell et al. (2017) model specific regions of the lung, such as the airway or alveolus, using human bronchial or alveolar epithelial cells combined with lung microvascular endothelial cells and non-small cell lung cancer cells. This approach highlights the critical role of the epithelial niche, as tumor growth rates differ depending on the local microenvironment. Moreover, the incorporation of cyclic mechanical strain mimicking breathing reveals that physical forces can significantly suppress tumor proliferation and invasion, while modulating key signaling pathways, thereby influencing therapeutic responses.(8)
A second type is represented by vascularized tumor spheroid chips, described by Paek et al. (2019), which integrate tumor cells, human endothelial cells, and fibroblasts within a fibrin-based extracellular matrix. These systems enable the self-assembly of perfusable microvascular networks that surround tumor spheroids, allowing drug delivery through the vasculature. This leads to more physiologically relevant responses, including spatially heterogeneous cytotoxic effects and the simultaneous evaluation of tumor and vascular toxicity, such as endothelial apoptosis and inflammatory activation.(9)
Finally, pre-vascularized tumor-on-chip platforms, such as the model developed by Shirure et al. (2023), rely on the formation of a stable microvascular network prior to tumor cell or organoid introduction. These platforms use endothelial cells to form quiescent vessels and incorporate various tumor types, including breast and colorectal cancer cell lines as well as patient-derived organoids. This configuration allows the study of dynamic processes such as proliferation, angiogenesis, migration, and intravasation, while also enabling the evaluation of drug responses in a context compatible with precision medicine.(10)
Biomechanics of the Tumor Microenvironment
Biomechanical stiffness is increasingly recognized as a meaningful biological marker in cancer-on-chip systems, revealing how physical properties of cells relate directly to their pathological state. Matrix stiffness plays an active role in tumor progression by inducing processes such as the epithelial-to-mesenchymal transition (EMT), which enhances invasiveness and metastatic potential through mechanotransduction pathways. [12]
Microfluidic platforms provide a powerful way to investigate these phenomena by applying controlled mechanical compressions on tumor models. In the journal Biofabrication 16 (2024) the chips is designed to allow for both compression on tumor spheroids while enabling high-resolution imaging. With use of finite element simulations, these systems allow precise spatial mapping of stiffness at the single-cell scale. Use cases of microfluidics and engineering offers a level of detail unattainable with traditional techniques. These mechanical differences are closely tied to the tissue’s structural organization, highlighting that tumor mechanics depend not only on intrinsic cellular properties but also on collective architecture. This insight paves the way for applying biomechanical analyses to patient-derived organoids, where tissue organization mirrors individual disease states and enables personalized mechanical profiling of tumors. (11)
Biochemical Signaling in the Tumor Microenvironment
The microenvironment (TME) is a highly dynamic system composed of cellular and non-cellular components, including the extracellular matrix (ECM), soluble factors, and mechanical cues. The ECM not only provides structural support but also regulates cell behavior through biochemical and biophysical signaling. Its composition reflects a balance between production and degradation, which becomes disrupted in cancer, leading to matrix remodeling that promotes tumor progression, invasion, and therapeutic resistance. (12)
In the central nervous system, the ECM is inherently distinct from that of other tissues, being largely lacks fibrillar proteins and enriched in proteoglycans, glycoproteins, and glycosaminoglycans such as hyaluronic acid. During glioblastoma (brain tumor) progression, this specialized matrix is extensively remodeled into a more complex and fibrillar environment. This transformation generates a hybrid ECM phenotype that critically regulates tumor invasion and must be accurately recapitulated in vitro. (13)
Functionally, the ECM acts as an active signaling platform. Cell surface receptors such as integrins and receptor tyrosine kinases convert biochemical and mechanical cues from the ECM into intracellular signals that promote cell proliferation, survival, and migration. In addition, collagen contributes directly to signaling through receptors, thereby enhancing tumor invasion and resistance to therapy. In addition, the interstitial space contains soluble factors that regulate tumor behavior through concentration gradients. Cytokines promote immunosuppression and ECM remodeling, while chemokines help maintain tumor cells in specific niches. Non-fibrillar ECM components play critical regulatory roles by modulating cell migration and proliferation via receptors, and acting as structural barriers that spatially organize tumor invasion. Together, these biochemical and structural features highlight the necessity of precisely controlling ECM composition and signaling cues in advanced in vitro models of brain tumors. (13)
In vitro cancer-on-chip models use defined ECM proteins to recreate tumor biochemical signaling. Collagen I remains the primary scaffold due to its ability to form 3D hydrogels that support tumor growth and invasion, with matrix density and fiber organization directly influencing cell behavior. However, its limited mechanical range has led to hybrid systems incorporating components to better mimic vascularization and enhance invasiveness.
Non-fibrillar components further refine biochemical signaling. Glycoproteins regulate adhesion and migration through integrin interactions, while peptide motifs enable precise control in synthetic matrices. Proteoglycans are widely used to tune stiffness and activate mechanosensitive pathways, particularly in glioblastoma models, highlighting the role of ECM composition in directing cell phenotype. (13)
To better capture in vivo complexity, multi-component and decellularized matrices are increasingly used. These systems preserve tissue-specific biochemical cues or allow fine-tuned control over ligand density and degradability, enabling dynamic cell–ECM interactions. (14)
Hypoxia and Oxygen Gradients in Tumor-on-Chip Models
Hypoxia is a hallmark of solid tumors and a key parameter to reproduce in tumor-on-chip models. In vivo, disorganized and leaky vasculature creates heterogeneous oxygen distributions, with hypoxic regions typically forming ~100 µm from blood vessels. Far from being a passive consequence of tumor growth, hypoxia actively drives malignancy through hypoxia-inducible factors, promoting angiogenesis, metabolic reprogramming, invasion, metastasis, and therapy resistance. Accordingly, tumor oxygen levels are significantly lower than in healthy tissues, emphasizing the need to replicate physiologically relevant conditions in vitro.
However, conventional culture systems fail to capture these features. Standard incubators maintain oxygen at ~141 mmHg, corresponding to hyperoxia rather than physiological levels, while hypoxic incubators equilibrate slowly, lack control over dissolved oxygen, and cannot generate spatial gradients. As a result, their relevance for modeling tumor microenvironments remains limited.(15)
To overcome these limitations, the Oxalis (OXygen ALImentation System) platform enables precise and dynamic control of dissolved oxygen in tumor-on-chip systems. It provides rapid equilibration with high accuracy, allowing faithful reproduction of clinically relevant oxygen levels. Importantly, Oxalis independently regulates oxygen, flow rate, CO₂ and pH, overcoming the intrinsic coupling between pressure and oxygen concentration in conventional microfluidics. Its biological relevance has been validated by the upregulation of hypoxia-responsive genes in cancer cells under controlled low-oxygen conditions. Achieving such precision requires the use of low oxygen-permeable materials, as common polymers such as PDMS allow significant oxygen diffusion. (16)
Beyond oxygen alone, hypoxia is tightly linked to fluid dynamics and extracellular matrix (ECM) mechanics. In tumors, leaky vasculature generates both oxygen gradients and elevated interstitial fluid pressure, driving interstitial flow through the ECM. This flow contributes to fibroblast activation, tumor cell migration, and angiogenesis, while associated shear stress can promote epithelial-to-mesenchymal transition and cancer stem cell phenotypes. These parameters are inherently interconnected, yet often coupled in microfluidic systems. By decoupling flow and oxygen control, platforms such as Oxalis enable stable perfusion at physiologically relevant shear stresses, while maintaining defined oxygen levels independently of cell density and proliferation.
From an ECM perspective, interstitial flow and pressure also regulate drug transport and immune cell infiltration, further highlighting the need for integrated control of physical and chemical cues. In this context, controlled perfusion plays a central role. Long-term unidirectional flow is essential for proper endothelial alignment and polarization, which are critical for modeling vascular function and permeability. Additionally, recirculation of conditioned medium enhances physiological relevance by preserving cell-secreted signaling factors, particularly important in hypoxic niches. Pressure-driven flow systems are especially well suited for these applications, as they provide stable low flow rates, minimize fluctuations, and maintain consistent oxygen conditions.
Overall, the integration of precise oxygen regulation with controlled fluid dynamics is essential for advancing tumor-on-chip models, enabling more accurate investigation of tumor biology, microenvironmental interactions, and therapeutic responses.
Applications of Cancer-on-a-Chip Technology
Drug Testing and Chemotherapy Response
One of the major unresolved challenges in oncology is identifying the most effective treatment for each individual patient. Conventional preclinical models, such as cell lines and patient-derived xenografts, provide valuable insights into general tumor biology but fail to capture the heterogeneity that ultimately determines therapeutic response at the patient level. Ex vivo tumor slice cultures have emerged as a promising alternative, as they preserve the native tumor microenvironment and allow direct drug testing. However, maintaining tissue viability beyond one week has remained a critical limitation. Traditional culture systems often generate harmful oxygen and nutrient gradients, introduce mechanical stress that disrupts tissue architecture, and fail to maintain stable physiological conditions over time. A key missing component has been a reliable, controlled perfusion system capable of supporting long-term culture under reproducible conditions.
To address these limitations, Erasmus MC and Bi/ond co-developed a Cancer-on-Chip platform based on silicon–PDMS microfluidic devices integrated into a 6-well plate format (COMPlate™). The system delivers culture medium simultaneously above and below the tumor slice, minimizing concentration gradients across the tissue thickness. Tumor slices are immobilized using a thermoreversible hydrogel that protects them from shear stress while remaining permeable to nutrients and gases. Continuous perfusion, a central feature of the platform, is ensured by Fluigent’s High Throughput Cell Perfusion Pack, which combines a pressure source (FLPG Plus), a multichannel flow controller (MFCS™-EZ), flow sensors (FLOW UNIT-S) for real-time monitoring of each well, and MAT software for automation and continuous data logging. The entire setup operates directly within a standard incubator, without requiring additional external infrastructure. (17)
The platform was validated using patient-derived xenografts models of breast cancer treated with cisplatin and prostate cancer treated with apalutamide. In both cases, the Cancer-on-Chip system successfully predicted therapeutic response, distinguishing sensitive from resistant tumors with greater accuracy than conventional ex vivo approaches. Continuous perfusion appears to improve drug delivery within the tissue compared to static culture conditions. In addition, the system maintains tissue viability, proliferation, and morphology for up to 14 days, which is twice as long as standard ex vivo cultures that typically begin to deteriorate within the first week. Transcriptomic analyses further show that the platform better preserves the gene expression profile of the original tumor, limiting stress-induced artifacts that could bias the interpretation of drug sensitivity.
The success of this approach relies strongly on the properties of the perfusion system. The pressure-driven technology provides a pulse-free flow, preventing cyclic mechanical stress that could damage fragile tumor slices over extended culture periods. Real-time monitoring of each channel enables immediate detection of any flow irregularities without interrupting the experiment. Moreover, the multichannel architecture allows multiple experimental conditions to be tested in parallel, which is essential for generating statistically robust data. The ease of use of the system also played a key role, allowing researchers without prior expertise in microfluidics to rapidly implement the platform and focus on biological questions rather than technical constraints.
Figure 7 Microfluidic Cancer-on-Chip Platform To Predict Drug Response
Immunotherapy and Metastasis Models
The development of organ-on-chip technologies offers a powerful alternative to conventional experimental models for studying cancer metastasis and evaluating immunotherapeutic strategies. Traditional in vivo models, while physiologically relevant, are constrained by ethical considerations and limited capacity to dissect specific signaling pathways. Conversely, standard in vitro systems lack the complexity required to faithfully reproduce the metastatic bone microenvironment. In this context, microfluidic cancer-on-chip platforms provide a controlled yet physiologically relevant framework to bridge this gap. [6]
In the journal Material Today Bio 13 (2022) the platform relies on a multi-compartment microfluidic architecture fabricated in PDMS using 3D-printed molds, representing an accessible alternative to conventional photolithography. It consists of three physically separated but paracrinally connected compartments hosting distinct human cell types: bone-tropic breast cancer cells cultured as 3D spheroids, human sympathetic neurons, and primary human osteoclasts seeded on a mineralized bone matrix. Pneumatic Quake valves enable precise control over inter-compartment communication, allowing selective modulation of signal directionality and the dissection of intercellular crosstalk. (6)
Biologically, this tri-culture system reveals a synergistic interaction between sympathetic neurons and osteoclasts that significantly influences tumor cell behavior. This interaction leads to an increased secretion of pro-inflammatory cytokines, within the tumor compartment. These cytokines are well-established mediators of bone metastasis progression and osteoclastogenesis, and they represent key targets in immunotherapeutic approaches. Importantly, selective disruption of communication between neuronal and osteoclastic compartments demonstrates that this synergy is primarily mediated through the tumor cells themselves, highlighting their central role as integrators of microenvironmental signals. (6)
From a pre-clinical perspective, the fully humanized nature of this model enhances its translational relevance. It provides a promising platform for investigating the role of the sympathetic nervous system in breast cancer progression, a therapeutic axis that remains debated, particularly regarding the clinical efficacy of β-blockers. Furthermore, the system is well-suited for pharmacological screening, enabling the evaluation of targeted inhibitors and signaling pathway modulators in a dynamic and physiologically relevant context.
Looking forward, this platform opens new avenues for immunotherapy research. The integration of immune components such as macrophages and lymphocytes would allow for a more comprehensive modeling of anti-tumor immune responses. Similarly, incorporating endothelial cells could enable the study of extravasation processes, while the addition of osteoblasts would further refine the bone metastatic niche. Ultimately, such advances could facilitate the development of personalized medicine approaches through the incorporation of patient-derived tumor samples, making cancer-on-chip systems a cornerstone of next-generation pre-clinical oncology research.
Circulating Tumor Cells Detection
Circulating tumor cells (CTCs) represent a critical biomarker for cancer diagnosis, prognosis, and treatment monitoring. However, their clinical exploitation remains challenging due to their extreme rarity and biological heterogeneity. Typically, circulating tumour cells occur at concentrations as low as one cell per millilitre of blood, among millions of leukocytes and billions of erythrocytes. This scarcity, combined with their phenotypic diversity, makes their isolation, characterization, and detection particularly demanding. Microfluidic technologies have emerged as powerful tools to address these challenges, enabling precise manipulation of fluids and cells at the microscale. In this context, high-performance flow control systems, play a central role by ensuring the stability and reproducibility required for reliable biological analyses. Recent advances illustrate a progressive integration of microfluidics into three key stages: specific capture, clonal analysis via encapsulation, and label-free detection. [19]
At the first level, microfluidics enables the selective capture and automated immunostaining of circulating tumour cells. Immunoaffinity-based approaches commonly rely on epithelial markers to isolate tumour cells from complex biological samples. In this context, advanced microfluidic platforms integrate functionalized magnetic beads that self-organize into three-dimensional filtering structures within microfabricated chips. These architectures enhance capture efficiency while preserving cell integrity. A crucial aspect of this approach is the automation of the fluidic workflow, which involves multiple sequential steps.
Systems such as Fluigent’s Aria enable the orchestration of complex injection sequences with high precision, ensuring consistent delivery of reagents throughout the protocol. Precise control of flow rates over a wide range is essential to minimize shear stress and ensure reproducibility, and pressure-based flow controllers provide the stability required for such delicate biological operations.
This highlights a fundamental principle in microfluidics: accurate and robust flow regulation is indispensable for maintaining biological viability and experimental consistency.
Building on this capability, microfluidics further enables the transition from cell capture to in-depth biological analysis through encapsulation and clonal sequencing. Droplet-based microfluidic systems allow the generation of monodisperse hydrogel spheres that encapsulate individual cells, creating isolated microenvironments for clonal expansion. This approach, combined with single-cell RNA sequencing techniques, reveals tumour heterogeneity at an unprecedented resolution. In particular, it enables the identification of rare subpopulations, such as cancer stem-like cells, that are often masked in bulk analyses. The generation of such droplets requires extremely fine control of flow rates and pressure to ensure uniform size and high throughput production.
Fluigent’s Flow-EZ pressure controllers, coupled with flow sensors and dedicated software, provide the level of precision and responsiveness necessary to generate stable droplets at high frequency. This demonstrates how microfluidics not only isolates circulating tumour cells but also provides access to their functional and genetic diversity, shifting from a purely sorting role to a platform for systems-level biological insight.
Finally, recent developments focus on label-free detection strategies that enhance the clinical translatability of microfluidic systems. Unlike traditional methods relying on molecular markers, these approaches exploit intrinsic physical properties of cells, such as optical phase shifts, to identify tumour cells. Interferometric imaging techniques integrated into microfluidic devices enable high-speed acquisition of quantitative phase images as cells flow through microchannels. In such systems, stable and ultra-low flow rates are critical to ensure image quality and compatibility with real-time data processing.
Pressure-based controllers such as Fluigent’s LineUp Flow-EZ ensure highly stable flow conditions, which are essential for consistent imaging and accurate downstream classification. Machine learning algorithms can then classify cells based on their morphological and biophysical signatures. This paradigm eliminates the need for labeling, reduces sample preparation complexity, and opens the way to non-invasive diagnostic applications, for example using urine or blood samples. (18)
Conclusion: Advancing Cancer Modeling Through Microfluidic and Organ-on-Chip Systems
Cancer-on-a-Chip technologies are redefining how we study and treat cancer by faithfully reconstructing the tumor microenvironment (TME) through advanced microfluidics cancer models, enabling a shift from simplified systems to dynamic, patient-relevant ecosystems. By integrating organ-on-chip approaches and sophisticated tumor-on-chip platforms, researchers can now capture the complexity of metastasis, biochemical and biomechanical signaling, and organ-specific tumor behavior, ultimately accelerating the development of more predictive therapies and personalized medicine strategies.
- Reproduces the full complexity of the tumor microenvironment (TME), including ECM, hypoxia, and cell–cell interactions
- Enables precise modeling of metastasis, extravasation, and organ-specific colonization
- Advances microfluidics cancer models for controlled, reproducible, and physiologically relevant experiments
- Leverages organ-on-chip systems to mimic tissue-specific environments and improve drug response prediction
- Supports personalized medicine through patient-derived tumor-on-chip and “tumor avatar” platforms
Related Microfluidic Solutions
Related content
-
Expert Reviews: Basics of Microfluidics Organ-on-chip Platforms in Modern Drug Development and Testing Read more
-
Expert Reviews: Basics of Microfluidics 5 Key Tips for Starting Organ-on-Chip Models Read more
-
Microfluidic Application Notes Liver–Kidney Organ-On-Chip Model using the Omi™ Dual Platform Read more
-
Microfluidics Case Studies Gut-on-Chip Modeling: From Chip Development to Perfusion Read more
-
Microfluidics Case Studies Mimicking tumor microenvironment using a 3D microfluidic model to improve cancer investigations Read more
-
Microfluidics Case Studies Creating a Microfluidic Cancer-on-Chip Platform using Fluigent’s High Throughput Cell Perfusion Pack Read more
-
Microfluidics White Papers A review of Organ on Chip Technology – A White Paper Read more
-
Expert Reviews: Basics of Microfluidics Why Control Shear Stress in Cell Biology? Read more
-
Microfluidic Application Notes Cancer Cell Analysis Made Easy with Aria: cell Capture and Labeling Read more
-
Microfluidic Application Notes Peristaltic Pump vs Pressure-Based Microfluidic Flow Control for Organ on Chip applications Read more
References
1. Xu H, Wen J, Yang J, Zhou S, Li Y, Xu K, et al. Tumor-microenvironment-on-a-chip: the construction and application. Cell Commun Signal. 2024 Oct 23;22(1):515. doi:10.1186/s12964-024-01884-4
2. Ahn J, Sei YJ, Jeon NL, Kim Y. Tumor Microenvironment on a Chip: The Progress and Future Perspective. Bioengineering. 2017 Jul 21;4(3). doi:10.3390/bioengineering4030064
3. Conceição F, Sousa DM, Loessberg-Zahl J, Vollertsen AR, Neto E, Søe K, et al. A metastasis-on-a-chip approach to explore the sympathetic modulation of breast cancer bone metastasis. Materials Today Bio. 2022 Jan 1;13:100219. doi:10.1016/j.mtbio.2022.100219
4. Saha B, Mathur T, Handley KF, Hu W, Afshar-Kharghan V, Sood AK, et al. OvCa-Chip microsystem recreates vascular endothelium–mediated platelet extravasation in ovarian cancer. Blood Adv. 2020 Jul 27;4(14):3329–42. doi:10.1182/bloodadvances.2020001632
5. Shin W, Kim HJ. 3D in vitro morphogenesis of human intestinal epithelium in a gut-on-a-chip or a hybrid chip with a cell culture insert. Nat Protoc. 2022 Mar;17(3):910–39. doi:10.1038/s41596-021-00674-3 PubMed PMID: 35110737; PubMed Central PMCID: PMC9675318.
6. Conceição F, Sousa DM, Loessberg-Zahl J, Vollertsen AR, Neto E, Søe K, et al. A metastasis-on-a-chip approach to explore the sympathetic modulation of breast cancer bone metastasis. Materials Today Bio. 2022 Jan 1;13:100219. doi:10.1016/j.mtbio.2022.100219
7. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022 Aug;23(8):467–91. doi:10.1038/s41576-022-00466-9 PubMed PMID: 35338360; PubMed Central PMCID: PMC8951665.
8. Hassell BA, Goyal G, Lee E, Sontheimer-Phelps A, Levy O, Chen CS, et al. Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro. Cell Reports. 2017 Oct 10;21(2):508–16. doi:10.1016/j.celrep.2017.09.043 PubMed PMID: 29020635.
9. Paek J, Park SE, Lu Q, Park KT, Cho M, Oh JM, et al. Microphysiological Engineering of Self-Assembled and Perfusable Microvascular Beds for the Production of Vascularized Three-Dimensional Human Microtissues. ACS Nano. 2019 Jul 23;13(7):7627–43. doi:10.1021/acsnano.9b00686
10. Shirure VS, Bi Y, Curtis MB, Lezia A, Goedegebuure MM, Goedegebuure SP, et al. Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids. Lab Chip. 2018 Dec 7;18(23):3687–702. doi:10.1039/c8lc00596f PubMed PMID: 30393802; PubMed Central PMCID: PMC10644986.
11. Jain S, Belkadi H, Michaut A, Sart S, Gros J, Genet M, et al. Using a micro-device with a deformable ceiling to probe stiffness heterogeneities within 3D cell aggregates. Biofabrication. 2024 Apr;16(3):035010. doi:10.1088/1758-5090/ad30c7
12. Faisal SM, Comba A, Varela ML, Argento AE, Brumley E, Abel C, et al. The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. Front Oncol. 2022 Oct 6;12. doi:10.3389/fonc.2022.1005069
13. Micek HM, Visetsouk MR, Masters KS, Kreeger PK. Engineering the Extracellular Matrix to Model the Evolving Tumor Microenvironment. iScience. 2020 Nov 20;23(11):101742. doi:10.1016/j.isci.2020.101742
14. Kutluk H, Bastounis EE, Constantinou I. Integration of Extracellular Matrices into Organ‐on‐Chip Systems. Adv Healthc Mater. 2023 Aug 8;12(20):2203256. doi:10.1002/adhm.202203256 PubMed PMID: 37018430; PubMed Central PMCID: PMC11468608.
15. Bouquerel C, Dubrova A, Hofer I, T. Phan DT, Bernheim M, Ladaigue S, et al. Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies. Lab on a Chip. 2023;23(18):3906–35. doi:10.1039/D3LC00531C
16. Bouquerel C, César W, Barthod L, Arrak S, Battistella A, Gropplero G, et al. Precise and fast control of the dissolved oxygen level for tumor-on-chip. Lab Chip. 2022 Nov 8;22(22):4443–55. doi:10.1039/D2LC00696K
17. A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture | Cancer Research | American Association for Cancer Research [Internet]. [cited 2026 Apr 3]. Available from: https://aacrjournals.org/cancerres/article/82/3/510/678034/A-Microfluidic-Cancer-on-Chip-Platform-Predicts
18. Dudaie M, Dotan E, Barnea I, Haifler M, Shaked NT. Detection of bladder cancer cells using quantitative interferometric label-free imaging flow cytometry. Cytometry Part A. 2024;105(8):570–9. doi:10.1002/cyto.a.24846